Universal Cells
Sarah Ameny has a background in Biology and Microbiology & Cell Science, with experience as a Research Associate and Research Technician at both Universal Cells and Fred Hutch. In their role, Sarah has worked on projects involving single cell sorting, antigen-specific memory B cells, flow cytometry, and neutralizing antibodies. Prior to their current roles, Sarah was an intern at Fred Hutch where Sarah worked on a project involving mouse colony maintenance, PCR genotyping, flow cytometry analysis, and immunohisto chemistry staining of cervical tissue samples.
Universal Cells
Universal Cells is a Seattle-based biotech developing, licensing and commercializing stem cell therapies that overcome immune rejection and can be used to create true off-the-shelf therapeutic products. Using the company's proprietary genome editing approach, the company engineers stem cells to prevent expression of polymorphic human leukocyteantigen (HLA) molecules, removing the cause of donor tissue rejection and creating Universal Donor Stem Cells that are compatible with every patient.